Drug Pipeline Monthly Update September 2017

Total Page:16

File Type:pdf, Size:1020Kb

Drug Pipeline Monthly Update September 2017 Drug Pipeline Monthly Update Critical updates in an ever changing environment September 2017 New drug information ● Zerviate™ (cetirizine ophthalmic solution): The U.S. Food and Drug Administration (FDA) approved Nicox Ophthalmic’s Zerviate for the twice daily treatment of ocular itching associated with allergic conjunctivitis. ● Benznidazole Tablets: The FDA granted accelerated approval to Chemo Research’s Benznidazole Tablets for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi in pediatric patients 2 to 12 years of age. Prior to approval, this drug was only available through the Centers for Disease Control and Prevention. The Chemo group worked with its U.S.-based pharmaceutical division Exeltis, as well as Mundo Sano and Drugs for Neglected Diseases initiative (DNDi) to complete the New Drug Application and notes that a substantial part of any revenue derived from the future sale of the neglected tropical disease priority review voucher they received will be directed towards enhancing access to treatment for Chagas patients and improving patient health in other disease areas.1 ● Zypitamag™ (pitavastatin magnesium): Zydus Pharmaceuticals received FDA approval for Zypitamag for high cholesterol. Zypitamag is an alternate salt product of Kowa Company Ltd’s Livalo® (pitastatin calcium). ● Admelog® (insulin lispro injection): The FDA granted tentative approval for Sanofi’s Admelog for the treatment of adults and children with diabetes mellitus. Tentative approval from the FDA means that Admelog met all necessary regulatory requirements for approval in the United States, pending any patent issues yet to be resolved. ● Adzenys™ ER (amphetamine): Neos Therapeutics received FDA approval of Adzenys ER, amphetamine extended-release oral suspension for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and older. Adzenys ER is considered bioequivalent to Shire’s Adderall® XR. ● Trelegy™ Ellipta® (fluticasone furoate, umeclidinium and vilanterol): GlaxoSmithKline and Innoviva received FDA approval of Trelegy Ellipta, a triple drug combination inhaler for the long-term, once-daily maintenance treatment of appropriate patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Trelegy Ellipta is the first inhaler to contain the combination of three drug classes in one inhaler: an inhaled corticosteroid, an anticholinergic, and a long-acting beta2-adrenergic agonist. While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner. Drug Pipeline Monthly Update: September 2017 Page 2 Generic Drug Information ● Sabril® (vigabatrin): Par Pharmaceuticals launched the first generic of Lundbeck’s Sabril, an adjunctive therapy for refractory complex partial seizures and a monotherapy for pediatric patients with infantile spasms. No patents or exclusivities remain. According to IMS, Sabril had approximately $329 million in U.S. sales over the past year. ● Fosrenol® (lanthanum): Natco Pharma/Lupin pharmaceuticals launched the first generic of Shire’s Fosrenol to reduce serum phosphate in patients with end stage renal disease (ESRD). Multiple manufacturers are awaiting FDA approval of their generic tablets. According to IMS, Fosrenol had $122.4 million in U.S. sales over the past year. Drug Pipeline Monthly Update: September 2017 Page 3 New molecular entity approvals in the past 12 months Generic name Brand name Manufacturer Indication(s) Date approved* benznidazole Benznidazole Chemo Research/ Chagas disease August 2017 Tablets DNDi/Mundo Sano betrixaban Bevyxxa™ Portola Prophylaxis of venous thromboembolism July 2017 delafloxacin Baxdela™ Melinta Skin infections June 2017 naldemedine Symproic® Shionogi Pain March 2017 safinamide Xadago® Newron Parkinson’s disease March 2017 Pharmaceuticals desmopressin nasal spray Noctiva™ Allergan and Serenity Nocturnal polyuria March 2017 house dust mite sublingual Odactra™ Merck, Sharp & House dust mite allergies March 2017 allergy immunotherapy Dohme plecanatide Trulance™ Synergy Chronic idiopathic constipation January 2017 crisaborole Eucrisa™ Pfizer/Anacor Mild to moderate atopic dermatitis December 2016 prasterone Intrarosa® Endoceutics Inc Pain during intercourse November 2016 *Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product’s manufacturer. Drug Pipeline Monthly Update: September 2017 Page 4 Other new product approvals in the past twelve months Generic name Brand name Manufacturer Indication(s) Date approved* fluticasone furoate, Trelegy™ Ellipta® GSK/Innoviva COPD September 2017 umeclidinium, vilanterol amphetamine extended release Adzenys™ ER Neos Therapeutics ADHD September 2017 suspension insulin lispro Admelog® Sanofi Diabetes August 2017 lesinurad/allopurinol Duzallo™ Ironwood Uncontrolled gout August 2017 Pharmaceuticals pitavastatin sodium Nikita™ Lupin High cholesterol August 2017 beclomethasone dipropionate Qvar® RediHaler™ Teva Teva August 2017 insulin glargine Lusduna® Nexvue™ Merck Diabetes August 2017 methylphenidate extended- Cotempla™ XR-ODT Neos Therapeutics ADHD July 2017 release orally disintegrating tablets mixed salts of a single-entity Mydayis™ Shire ADHD July 2017 amphetamine products pitavastatin Zipitamag Zydus High cholesterol July 2017 epinephrine injection Symjepi™ Adamis Allergic reactions June 2017 Pharmaceuticals Corporation cetirizine ophthalmic solution Zerviate™ Nicox Ophthalmic Eye itching May 2017 methotrexate solution Xatmep™ Silvergate ALL and arthritis in pediatric patients April 2017 Pharmaceuticals oxycodone, immediate-release RoxyBond™ Inspirion/ Pain, abuse deterrent April 2017 Daiichi Sankyo dapagliflozin/saxagliptin Qtern™ AstraZeneca Diabetes February 2016 lisdexamfetamine (chew tab) Vyvanse® Shire ADHD February 2017 naloxone nasal spray, 2 mg Narcan® Adapt Pharma Inc Opioid overdose January 2016 fluticasone propionate ArmonAir™ Teva Asthma January 2016 RespiClick® fluticasone AirDuo™ Teva Asthma January 2016 propionate/salmeterol RespiClick® oxymetazoline Rhofade™ Allergan Rosacea January 2016 hydrocodone extended release Vantrela™ ER Teva Pain, abuse deterrent January 2016 morphine extended release Arymo™ ER Egalet Pain, abuse deterrent January 2016 insulin glargine Basaglar™ Eli Lilly Diabetes December 2015, launched in December 2016 empagliflozin/metformin Synjardy® XR Eli Lilly Diabetes December 2016 extended release Lantus® (insulin glargine)/ Soliqua™ Sanofi Diabetes November 2016 Adlyxin™ (lixisenatide) Tresiba® (insulin degludec/ Xultophy® Novo Nordisk Diabetes November 2016 Victoza® (liraglutide) Drug Pipeline Monthly Update: September 2017 Page 5 Other new product approvals in the past twelve months contined Generic name Brand name Manufacturer Indication(s) Date approved* doxylamine/pyridoxine XR Bonjesta® Duchesnay Pregnancy-related nausea and vomiting November 2016 tenofovir alafenamide Vemlidy® Gilead Hepatitis B November 2016 mebendazole Vermox® Johnson & Johnson/ Parasitic disease November 2016 Janssen norethindrone/estradiol fe Taytulla™ Apil Pregnancy prevention October 2016 sumatriptan/naproxen Treximet® Permix Migraine October 2016 *Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product’s manufacturer. Pipeline watch Anticipated FDA Generic name Brand name Manufacturer Indication(s) decision date ITCA 650 (exenatide mini-pump) N/A Intarcia Diabetes September 2017 secnidazole Solosec™ Symbiomix Bacterial vaginosis September 2017 insulin aspart FIAsp™ Novo Nordisk Diabetes September 2017 tadalafil PharmFilm® N/A MonoSol RX ED September 2017 aripiprazole, digital tablet Abilify® Otsuka, Proteus Health Drug/device combo for schizophrenia, 4th Quarter 2017 bipolar disorder and major depression testosterone enanthate Xyosted™ Antares Testosterone replacement October 2017 auto-injector QuickShot™ Pharmaceuticals rolapitant N/A Tesaro, Opko Health Chemotherapy-induced nausea and October 2017 vomiting aprepitant Cinvanti™ Heron Therapeutics Chemotherapy-induced nausea and November 2017 vomiting buprenorphine monthly depot N/A Indivior Opioid use disorder November 2017 semaglutide N/A Novo Nordisk Diabetes December 2017 ertugliflozin N/A Merck/Pfizer Diabetes December 2017 ertugliflozin/metformin N/A Merck/Pfizer Diabetes December 2017 ertugliflozin/sitagliptin N/A Merck/Pfizer Diabetes December 2017 acetaminophen/ibuprofen Maxigesic® AFT Pharmaceuticals Pain December 2017 SUN-101/eFlow (glycopyrrolate) N/A Sunovion COPD December 2017 Pharmaceuticals Inc dolutegravir/rilpivirine N/A Viiv Healthcare HIV-1 infection December 2017 ethinyl estradiol/ Twirla™ Agile Therapeutics Pregnancy prevention December 2017 levonorgestrel transdermal Drug Pipeline Monthly Update: September 2017 Page 6 Pipeline watch contined Anticipated FDA Generic name Brand name Manufacturer Indication(s) decision date testosterone undecanoate Jatenzo™ Clarus Therapeutics Testosterone replacement December 2017 mometasone furoate sinus Sinuva™ Intersect ENT Chronic sinusitis January 2017 implant buprenorphine FluidCrystal® N/A Braeburn Opioid use disorder January 2018 Pharmaceuticals polyethylene
Recommended publications
  • List of Medicinal Products Under Additional Monitoring
    26 October 2018 EMA/245297/2013 Rev.60 Inspections & Human Medicines Pharmacovigilance List of medicinal products under additional monitoring Related Information: Additional monitoring explained: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000365.jsp Good Pharmacovigilance Practice Module on additional monitoring: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp To note: All products added to the list in September 2018 are shown in red font. All products removed from the list are shown with a strikethrough for the period of one month after which they are excluded. Date of Product name Active Substance (s) Reason (s) on list Marketing Authorisation Holder (s) Link to Product Information Inclusion http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ Abasaglar (previously Abasria) Insulin glargine New biological Eli Lilly Nederland B.V. 002835/human_med_001790.jsp&mid=WC0b01ac058001d124 October 2014 Acarizax (also known in some EU countries as MITIZAX) Standardised allergen extract from house dust mites New Biological ALK-Abelló A/S https://portal.dimdi.de/amispb/doc/pei/Web/2613318-spcde-20170401.pdf May 2016 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ Accofil Filgrastim New biological Accord Healthcare Limited 003956/human_med_001798.jsp&mid=WC0b01ac058001d124 October 2014 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ Adcetris Brentuximab vedotin
    [Show full text]
  • Eortc-1307-Bcg) (Big5-13) (Tesaro Pr-30-5010-C)
    EORTC Avenue E. Mounierlaan 83/11 Brussel 1200 Bruxelles België – Belgique Tel: PPD e-mail: PPD www.eortc.org Intergroup Study (EORTC-1307-BCG) (BIG5-13) (TESARO PR-30-5010-C) (EudraCT number 2013-000684-85) (NCT01905592) (IND number # 117580) A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. Co-Lead: Breast International Group (BIG) EORTC Breast Cancer Group Study Coordinator: PPD (BIG) Study Co-Coordinators: PPD (BIG) PPD (EORTC) PPD (Tufts Medical Center) Protocol Date of PRC Amendment reference version approval/notification N° Classification Outline June 28, 2013 ---- ---- 1.0 July 22, 2013 ---- ---- 2.0 August 28, 2013 1 Scientific 3.0 April 24, 2014 3 Scientific 4.0 May 04, 2015 4 Scientific 5.0 November 04, 2015 5 Scientific 6.0 January 13, 2017 8 Scientific Version 6.0 / January 13, 2017 Copyright EORTC 2017 EORTC-1307-BCG / BIG5-13 / TESARO PR-30-5010-C Niraparib in BRCA germline mutated MBC Contact addresses Executive Committee: Defined in the related study charter Writing Committee: PPD (EORTC, Statistician) PPD (EORTC, Study Co-coordinator) PPD (Tufts Medical Center) PPD (BIG, Scientific Director) PPD (BIG, Ass. Scientific Director) PPD (EORTC, Statistician) PPD (EORTC, Clinical Research Physician) PPD (BIG, Study Coordinator) Steering Committee: Defined in the related study charter Version 6.0 2 / 102 January 13, 2017 EORTC-1307-BCG / BIG5-13 / TESARO PR-30-5010-C Niraparib
    [Show full text]
  • January 2020: Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 01 : January 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> AA XIROMED 325MG;5MG A 211690 001 Feb 07, 2020 Jan NEWA >A> AA 325MG;7.5MG A 211690 002 Feb 07, 2020 Jan NEWA >A> AA 325MG;10MG A 211690 003 Feb 07, 2020 Jan NEWA ACYCLOVIR CREAM;TOPICAL ACYCLOVIR >D> AB PERRIGO UK FINCO 5% A 208702 001 Feb 04, 2019 Jan CHRS >A> AB ! 5% A 208702 001 Feb 04, 2019 Jan CHRS ZOVIRAX >D> AB +! BAUSCH 5% N 021478 001 Dec 30, 2002 Jan CHRS >A> AB + 5% N 021478 001 Dec 30, 2002 Jan CHRS OINTMENT;TOPICAL ACYCLOVIR >A> AB XIROMED 5% A 201501 001 Jan 29, 2020 Jan NEWA TABLET;ORAL ACYCLOVIR >D> AB HETERO LABS LTD V 800MG A 203834 002 Oct 29, 2013 Jan CHRS >A> AB ! 800MG A 203834 002 Oct 29, 2013 Jan CHRS >D> ZOVIRAX >D> AB + MYLAN 400MG N 020089 001 Apr 30, 1991 Jan DISC >A> + @ 400MG N 020089 001 Apr 30, 1991 Jan DISC >D> AB +! 800MG N 020089 002 Apr 30, 1991 Jan DISC >A> + @ 800MG N 020089 002 Apr 30, 1991 Jan DISC AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL EMULSION;INTRAVENOUS PERIKABIVEN IN PLASTIC CONTAINER >D> + FRESENIUS KABI USA 2.4%;20MG/100ML;6.8GM/100ML;68M N 200656 003 Aug 25, 2014 Jan CHRS G/100ML;124MG/100ML;170MG/100ML ;105MG/100ML;3.5GM/100ML (2400ML) >A> +! 2.4%;20MG/100ML;6.8GM/100ML;68M N 200656 003 Aug 25, 2014 Jan CHRS G/100ML;124MG/100ML;170MG/100ML
    [Show full text]
  • Final Belgian List
    Final Belgian list: (Last update 07/02/2019) Marketing name Active substance MAH Reason on list ABASAGLAR (ABASRIA previously)INSULINE GLARGINE ELI LILLY REGIONAL OPERATIONS GMBH New Biological ACARIZAX STANDARDIZED ALLERGEN EXTRACT FROM HOUSE DUSTALK-ABELLO MITES A/S New Biological ACCOFIL FILGASTRIM ACCORD HEALTHCARE LIMITED New Biological ADCETRIS BRENTUXIMAB VEDOTINE TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD New AS, Cond Auth, PASS ADEMPAS RIOCIGUAT BAYER PHARMA New AS ADYNOVI RURIOCTOCOG ALFA PEGOL BAXALTA INNOVATIONS GMBH New AS, PASS AIMOVIG ERENUMAB NOVARTIS EUROPHARM LIMITED New AS, New Biological AFSTYLA LONOCTOCOG ALFA CSL BEHRING GmbH New AS STANDARDIZED ALLERGEN EXTRACT FROM HOUSE AITARO ALK-ABELLO A/S New Biological DUST MITES AKYNZEO NETUPITANT, PALONOSETRON HELSINN BIREX PHARMACEUTICALS LTD New AS ALECENSA ALECTINIB ROCHE REGISTRATION LIMITED New AS, Cond Auth ALOFISEL DAVASTROCEL TiGenix SAU New AS ALPHA-RIX TETRA INFLUENZA VACCINE INACTIVATED GLAXOSMITHKLINE BIOLOGICALS S.A. New Biological ALPIVAB PERAMIVIR BIOCRYST UK LTD New AS ALPROLIX EFTRENOCOG ALFA BIOGEN IDEC LTD New AS ALUNBRIG BRIGATINIB TAKEDA PHARMA A/S New AS AMGEVITA ADALIMUMAB AMGEN EUROPE BV New biological STANDARDIZED ALLERGEN EXTRACT FROM HOUSE AMITEND ALK-ABELLO A/S New Biological DUST MITES AMITIZA LUBIPROSTON Sucampo Pharma Europe Ltd New AS ANORO GLAXO GROUP LTD New AS, PASS UMECLIDINIUM BROMIDE, VILANTEROL TRIFENATATE APLEEK ETHINYL ESTRADIOL/GESTODENE BAYER PHARMA AG PASS ATRIANCE NELARABINE 5.00 MG/ML GLAXO GROUP LTD Auth under excep circumstances
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Available Medications and Supplies
    Available Medications and Supplies * Denotes "Restricted Name Strength Units Dosage Form Generic Name Program Name AWP ARP Medications 8-MOP 10 MG CAPSULE(S) METHOXSALEN Valeant Patient Assistance Program $1,843.80 $2,120.37 ABACAVIR (BRAND: ZIAGEN) 300 MG TABLET(S) ABACAVIR Xubex Preferred Network Program $603.33 $693.83 ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE (BRAND: TRIZIVIR) 300-150-300 MG-MG-MG TABLET(S) ABACAVIR SULFATE, Xubex Preferred Network Program $1,738.46 $1,999.23 LAMIVUDINE AND ZIDOVUDINE ABELCET 5 MG/ML (20 ML) MG AMPHOTERICIN B LIPID Sigma-Tau Patient Assistance Program $240.00 $276.00 COMPLEX ABILIFY * 1 MG/ML (150 ML) ML ARIPIPRAZOLE Bristol-Myers Squibb Patient Assistance $1,177.87 $1,354.55 Foundation, Inc. * 2 MG TABLET(S) ARIPIPRAZOLE Bristol-Myers Squibb Patient Assistance $1,070.36 $1,230.91 Foundation, Inc. * 20 MG TABLET(S) ARIPIPRAZOLE Bristol-Myers Squibb Patient Assistance $5,045.42 $5,802.23 Foundation, Inc. * 5 MG TABLET(S) ARIPIPRAZOLE Bristol-Myers Squibb Patient Assistance $3,567.66 $4,102.81 Foundation, Inc. ABILIFY * 10 MG TABLET(S) ARIPIPRAZOLE Bristol-Myers Squibb Patient Assistance $3,567.66 $4,102.81 Foundation, Inc. * 15 MG TABLET(S) ARIPIPRAZOLE Bristol-Myers Squibb Patient Assistance $3,567.66 $4,102.81 Foundation, Inc. Report Run: 04/19/16 10:53 AM Page 1 of 377 Available Medications and Supplies * Denotes "Restricted Name Strength Units Dosage Form Generic Name Program Name AWP ARP Medications ABILIFY * 30 MG TABLET(S) ARIPIPRAZOLE Bristol-Myers Squibb Patient Assistance $5,045.42 $5,802.23 Foundation, Inc.
    [Show full text]
  • GSK Delivers Q2 Sales of £7.6 Billion -2% AER, -3% CER (Pro-Forma -10% CER*) Total EPS 45.5P >100% AER; >100% CER; Adjusted EPS 19.2P -37% AER, -38% CER
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020 Commission File Number 001-15170 GlaxoSmithKline plc (Translation of registrant's name into English) 980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F . .X. Form 40-F . Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ Issued: Wednesday, 29 July 2020, London U.K. GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*) Total EPS 45.5p >100% AER; >100% CER; Adjusted EPS 19.2p -37% AER, -38% CER Financial and product highlights ● Reported Group sales £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*; -8% CER excluding divestments/brands under review). Pharmaceuticals £4.1 billion -5% AER, -5% CER; Vaccines £1.1 billion -29% AER, -29% CER; Consumer Healthcare £2.4 billion +25% AER, +25% CER (Pro-forma -6% CER) ● H1 Reported group sales £16.7 billion 8% AER, 8% CER (Pro-forma flat CER*; +1% CER excluding divestments/brands under review) ● Sales decline in Q2 2020 reflects expected disruption from COVID-19, particularly in Vaccines as well as destocking from Q1 2020 in Pharmaceuticals and Consumer Healthcare ● Total Respiratory sales £883 million +17% AER, +16% CER.
    [Show full text]
  • October Through December 2013
    October through December 2013 precautions about the risk of blood clots and severe Updated Warnings—Current Drugs narrowing of blood vessels, revise recommendations about dosage and administration of Iclusig, and update the patient Medication Guide. We are also requiring a risk Mass Destruction Muscle Growth—Safety Risk: The evaluation and mitigation strategy (REMS). In addition, FDA is advising consumers to immediately stop using a the manufacturer of Iclusig, ARIAD Pharmaceuticals, must product called Mass Destruction, marketed as a dietary conduct postmarket investigations to further characterize supplement for muscle growth. The product is labeled to the drug’s safety and dosing. contain at least one synthetic anabolic steroid and has been On October 31, 2013, FDA requested and ARIAD agreed to linked to at least one reported serious illness. The product’s voluntarily suspend marketing of Iclusig. FDA’s request ingredients are undergoing further analysis by the FDA. resulted from FDA’s investigation, which revealed a steady Liver injury is generally known to be a possible outcome of increase in the number of serious vascular occlusion events using products that contain anabolic steroids and steroid- identified through continued safety monitoring of the drug. like substances. In general, anabolic steroids may cause This observation represented a significant change in the other serious long-term consequences in women, men, and safety profile of Iclusig as the proportion of patients on the children. These include adverse effects on blood lipid lev- drug experiencing vascular occlusion events such as blood els, increased risk of heart attack and stroke, masculiniza- clots and severe narrowing of blood vessels was tion of women, shrinkage of the testicles, breast enlarge- significantly greater than the proportion reported at the ment, infertility in males, and short stature in children.
    [Show full text]
  • Wednesday, February 14, 2018 4:00Pm
    Wednesday, February 14, 2018 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Bethany Holderread, Pharm.D. SUBJECT: Packet Contents for Board Meeting – February 14th, 2018 DATE: January 26, 2018 NOTE: The DUR Board will meet at 4:00 p.m. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the February meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Chronic Medication Adherence Program Update – Appendix B Action Item – Vote to Prior Authorize Zerviate™ (Cetirizine Ophthalmic Solution) – Appendix C Action Item – Vote to Prior Authorize ArmonAir™ RespiClick® (Fluticasone Propionate), Trelegy™ Ellipta® (Fluticasone Furoate/Umeclidinium/Vilanterol), QVAR® RediHaler™ (Beclomethasone Dipropionate), AirDuo™ RespiClick® (Fluticasone Propionate/Salmeterol), and Fasenra™ (Benralizumab) and to Update Nucala® (Mepolizumab) and Xolair® (Omalizumab) Criteria – Appendix D Action Item – Vote to Prior Authorize Emflaza® (Deflazacort) – Appendix E Action Item – Vote to Prior Authorize Zilretta™ (Triamcinolone Acetonide Extended-Release Injectable Suspension) – Appendix F Action Item – Vote to Prior Authorize Varubi® IV (Rolapitant) and Cinvanti™ (Aprepitant) – Appendix G Action Item – Annual Review of Seizure Medications – Appendix H Annual Review of Osteoporosis Medications and 30-Day Notice to Prior Authorize Tymlos™ (Abaloparatide) – Appendix I Annual Review of Antiviral Medications and 30-Day Notice to Prior Authorize Prevymis™ (Letermovir Tablets and Injection) – Appendix J Annual Review of Glaucoma Medications and 30-Day Notice to Prior Authorize Rhopressa® (Netarsudil Ophthalmic Solution) and Vyzulta™ (Latanoprostene Bunod Ophthalmic Solution) – Appendix K ORI-4403 • P.O.
    [Show full text]
  • Annual Report 2020 We Are a Science-Led Global Healthcare Company
    Annual Report 2020 We are a science-led global healthcare company 2020 performance summary £34.1bn AER +1% £9.7bn AER +11% Group turnover CER +3% New and specialty medicines CER +12% £7.8bn AER +12% £8.9bn AER - 1% Total operating profit CER +15% Adjusted operating profit CER +2% 115.5p AER +23% 115.9p AER - 6% Total earnings per share CER +26% Adjusted earnings per share CER - 4% 9 80p 1st 2nd major pipeline Dividend in the Access to in the pharmaceutical approvals Medicine Index industry for Dow Jones Sustainability Index Contents Strategic report Our business model 01 Board roles and responsibilities 86 Financial statements of Chairman’s statement 03 Board activity and principal decisions 87 GlaxoSmithKline plc prepared CEO’s statement 04 Our purpose, values and culture 90 under UK GAAP 238 Financial performance 06 The Board’s approach to engagement 91 Our long-term priorities 09 Board performance 94 Investor information Our culture 10 Board Committee information 96 Quarterly trend 244 Key performance indicators 11 Our Board Committee reports 97 Five-year record 249 Industry trends 12 Section 172 statement 108 Product development pipeline 255 Stakeholder engagement 16 Directors’ report 109 Products, competition and Innovation 18 intellectual property 258 Remuneration report Performance 28 Principal risks and uncertainties 261 Trust 33 Chairman’s annual statement 112 Share capital and share price 276 Risk management 43 Annual report on remuneration 114 Dividends 278 Group financial review 50 2020 Remuneration policy summary 133 Financial
    [Show full text]
  • 5 CLINICAL NEWS 16 FINANCIAL NEWS Deals, Sales & Marketing, Other Regulatory, Clinical Results, Completed Offerings, Other News Clinical Status Financial News
    WEEK OF SEPTEMBER 25, 2017 1 COMPANY NEWS 5 CLINICAL NEWS 16 FINANCIAL NEWS Deals, Sales & Marketing, Other Regulatory, Clinical Results, Completed Offerings, Other News Clinical Status Financial News COMPANY NEWS line data are expected in mid-2018 from Phase III trials to treat myelodysplastic syndromes (MDS) and beta-thalassemia (see DEALS BioCentury, Aug. 8, 2011). Luspatercept is a modifiedACVR2B fusion protein that inhibits Acceleron Pharma Inc. (NASDAQ:XLRN), Cambridge, Mass. several ligands in the transforming growth factor (TGF) beta (NASDAQ:CELG), Summit, N.J. Celgene Corp. superfamily. Business: Cancer, Hematology, Cardiovascular Acceleron Pharma Inc. (NASDAQ:XLRN) gained worldwide Arcus Biosciences, Hayward, Calif. rights to develop and commercialize sotatercept to treat pulmonary Taiho Pharmaceutical Co. Ltd., Tokyo, Japan hypertension, amending a deal with partner Celgene Corp. Business: Cancer (NASDAQ:CELG). Acceleron expects to begin a Phase II trial of Cancer company Arcus Biosciences (Hayward, Calif.) granted Taiho sotatercept to treat pulmonary arterial hypertension (PAH) in 1H18. Pharmaceutical Co. Ltd. (Tokyo, Japan) an option to develop and In 2008, Acceleron and Celgene partnered to co-develop and commercialize compounds in Japan and other Asian territories commercialize Acceleron's sotatercept for all indications, with an excluding China. Arcus said the deal includes anything listed on its initial focus on cancer, including breast and ovarian cancers, and pipeline chart. cancer-related bone loss. At the time, Acceleron received $50 million Arcus will receive $35 million over the first three years of the five- up front, including a $5 million equity investment by Celgene, and year agreement and is eligible to receive up to $275 million in was eligible for up to $510 million in milestones, plus tiered royalties milestones for each molecule, plus high-single to mid-double-digit (see BioCentury, Feb.
    [Show full text]
  • Group Companies
    Strategic report Governance and remuneration Financial statements Investor information Other statutory disclosures continued Group companies In accordance with Section 409 of the Companies Act 2006 a full list of subsidiaries, associates, joint ventures and joint arrangements, the address of the registered office and effective percentage of equity owned, as at 31 December 2019 are disclosed below. Unless otherwise stated the share capital disclosed comprises Ordinary shares which are indirectly held by GlaxoSmithKline plc. The percentage held by class of share is stated where this is less than 100%. Unless otherwise stated, all subsidiary companies have their registered office and are tax resident in their country of incorporation. Name Security Registered address Wholly owned subsidiaries 1506369 Alberta ULC Common 3500 855-2nd Street SW, Calgary, AB, T2P 4J8, Canada Action Potential Venture Capital Limited Ordinary 980 Great West Road, Brentford, Middlesex, TW8 9GS, England Adechsa GmbH (ii) Ordinary c/o PRV Provides Treuhandgesellschaft AG, Dorfstrasse 38, Baar, 6341, Switzerland Affymax Research Institute Common Corporation Service Company, 2710 Gateway Oaks Drive, Suite 150N, Sacramento, California, 95833, United States Alenfarma – Especialidades Farmaceuticas, Limitada (ii) Ordinary Quota Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, 1495-131, Portugal Allen & Hanburys Limited (ii) Ordinary 980 Great West Road, Brentford, Middlesex, TW8 9GS, England Allen & Hanburys Pharmaceutical Nigeria Limited Ordinary 24 Abimbola Way, Ilasamaja, Isolo, Lagos, Nigeria Allen Farmaceutica, S.A. Ordinary Severo Ochoa, 2, Parque Tecnologico de Madrid, Tres Cantos, Madrid, 28760, Spain Allen Pharmazeutika Gesellschaft m.b.H. Ordinary Wagenseilgasse 3, Euro Plaza, Gebäude I, 4. Stock, Vienna, A-1120, Austria Barrier Therapeutics, Inc.
    [Show full text]